Overview
CJC-1295 is a modified synthetic analog of GHRH (Growth Hormone Releasing Hormone, or somatoliberin), the natural hypothalamic hormone responsible for stimulating growth hormone (GH) secretion from the anterior pituitary. Developed by ConjuChem Biotechnologies, this 29-amino acid peptide was designed to overcome the pharmacokinetic limitations of native GHRH, which has a plasma half-life of only a few minutes.
The key modification of CJC-1295 lies in the incorporation of Drug Affinity Complex (DAC) technology, which enables reversible covalent binding to serum albumin. This bioconjugation considerably extends the peptide's half-life, increasing it from a few minutes (native GHRH) to approximately 6 to 8 days. There is also a version without DAC (CJC-1295 no DAC, or Mod GRF 1-29) with an intermediate half-life of approximately 30 minutes.
CJC-1295 is the subject of research in the context of growth hormone deficiencies, aging, and body composition. Its interest lies in its ability to stimulate the natural pulsatile secretion of GH, unlike direct exogenous administration of recombinant growth hormone, thus preserving physiological feedback mechanisms.
Two different molecules share the CJC-1295 name. The figures given above are those of CJC-1295 with DAC, the molecule described in this guide: molecular formula C165H269N47O46 and a molecular weight of about 3647.95 g/mol. CJC-1295 without DAC, sold as mod GRF 1-29, is C152H252N44O42 and about 3367.95 g/mol, because it lacks the maleimidopropionamide lysine that carries the albumin conjugation. The 29-amino-acid sequence shown above is the GHRH(1-29) backbone common to both; the DAC form adds that modified lysine at the C terminus (Jetté et al. 2005). The US Food and Drug Administration treats them as two distinct active moieties and five distinct bulk substances in its 2024 evaluation, and vendor listings frequently mix the two sets of values.
Mechanism of Action
CJC-1295 acts by binding to the GHRH receptor (GHRHR) expressed on the surface of somatotropic cells of the anterior pituitary. This receptor belongs to the class B (secretin) family of G protein-coupled receptors. Activation of the GHRHR triggers a signaling cascade involving the Gs protein, adenylate cyclase, and cAMP, leading to the opening of voltage-dependent calcium channels and exocytosis of secretory granules containing GH.
Unlike native GHRH, which is rapidly inactivated by dipeptidyl peptidase-IV (DPP-IV) within minutes, CJC-1295 incorporates structural modifications that protect it from this enzymatic degradation. The D-Ala substitution at position 2 confers resistance to DPP-IV, while the DAC technology (in the CJC-1295 DAC version) allows binding to circulating albumin, creating a sustained-release peptide reservoir.
The effect of CJC-1295 on GH secretion is pulsatile and dose-dependent. The peptide amplifies the amplitude of natural GH secretory pulses without altering their frequency, thus preserving the circadian rhythm of somatotropic secretion. This property distinguishes it from direct administration of recombinant GH, which suppresses endogenous secretion through negative feedback. CJC-1295 also stimulates IGF-1 (Insulin-like Growth Factor-1) secretion by the liver, the primary mediator of the anabolic and metabolic effects of GH.
Studied Benefits
Increased GH and IGF-1 secretion
Phase I/II clinical studies have shown that CJC-1295 DAC increases plasma GH levels by 2- to 10-fold and IGF-1 levels by 1.5- to 3-fold compared to baseline values, with a sustained effect lasting 6 to 14 days after a single injection. These increases are dose-dependent and reproduce a more physiological secretory profile than direct GH injection.
Improved body composition
Preclinical research and preliminary clinical data suggest that the prolonged GH/IGF-1 increase induced by CJC-1295 could promote increased lean mass and reduced fat mass. These effects are consistent with the known actions of the GH/IGF-1 axis on protein and lipid metabolism.
Potential for age-related GH deficiency
GH secretion progressively declines with age (somatopause), contributing to sarcopenia, increased adiposity, and decreased bone density. CJC-1295 is being studied as a potential alternative to recombinant GH replacement therapy, with the theoretical advantage of preserving natural secretory pulsatility.
Improved sleep quality
GH is primarily secreted during slow-wave sleep (stages 3 and 4 of NREM sleep). Preliminary data suggest that GH axis stimulation by CJC-1295 could improve sleep architecture and increase the proportion of deep sleep, although these observations require confirmation through controlled polysomnographic studies.
Research Status
The clinical development of CJC-1295 was initiated by ConjuChem Biotechnologies with Phase I and II trials conducted in the 2000s. The pivotal study by Teichman and collaborators (2006) demonstrated that CJC-1295 DAC significantly and sustainably increases GH and IGF-1 levels in healthy adults, with good tolerability at the doses tested (30 to 60 mcg/kg). These results constituted an important proof of concept for the use of long-acting GHRH analogs.
However, the clinical development program was halted following serious adverse events, including a death that occurred during a clinical trial, although a definitive causal link with CJC-1295 was not established. This interruption considerably slowed progression toward Phase III trials. Since then, research has shifted toward the version without DAC (Mod GRF 1-29) and combinations with GH secretagogues (GHRP).
The current state of research is classified as preclinical to early clinical. Existing data clearly demonstrate the pharmacodynamic efficacy of CJC-1295 in increasing GH and IGF-1, but questions regarding long-term safety, therapeutic efficacy on relevant clinical endpoints, and the benefit/risk ratio remain insufficiently documented. The peptide is listed on the World Anti-Doping Agency (WADA) prohibited substances list in the S2 category.
The phase 2 trial behind that interruption can now be identified: ConjuChem registered it as NCT00267527, a multicentre, randomised, placebo-controlled study in HIV-infected adults with HIV-associated visceral obesity, started in December 2005 and later terminated. According to the account FDA reconstructed for its 2024 advisory committee briefing, one participant complained of chest discomfort about two hours after an eleventh weekly injection, an ECG confirmed an acute myocardial infarction, and the participant died approximately one hour later. The attending physician stated that his most likely explanation was asymptomatic coronary artery disease with plaque rupture and occlusion. No independent causality assessment was ever published, the trial data were never published either, and FDA notes that the available description comes from contemporaneous press reports rather than from a peer-reviewed publication.
Safety and Side Effects
Safety data for CJC-1295 come primarily from Phase I/II clinical trials and preclinical studies. The most frequently reported side effects in clinical trials include injection site reactions (redness, induration, pain), transient flushing, diarrhea, and headaches. These effects were generally mild to moderate and dose-dependent.
Potential adverse effects related to chronic GH/IGF-1 elevation represent an important theoretical concern. Excessive and prolonged stimulation of the somatotropic axis could theoretically induce effects similar to acromegaly: fluid retention, arthralgia, carpal tunnel syndrome, insulin resistance, and potentially an increased risk of proliferation of certain IGF-1-sensitive tumor cells. These risks underscore the need for rigorous medical monitoring.
The most serious event during clinical development was the death of a participant during a trial, which led to the interruption of ConjuChem's clinical program. Although the investigation did not establish a definitive causal link with CJC-1295, this event illustrates the inherent risks of manipulating the GH/IGF-1 axis. The use of CJC-1295 outside of a supervised clinical research setting is not recommended and carries unquantified risks.
Regulatory and anti-doping status
No approval anywhere. CJC-1295 is not an approved medicine in the United States, the European Union or any other major jurisdiction, and it is not a component of any FDA-approved drug. Its clinical development stopped in 2006 and no sponsor has registered a new trial since. In the United States the question that has been examined is narrower: whether CJC-1295 may be used as a bulk substance in pharmacy compounding. In a briefing prepared for the Pharmacy Compounding Advisory Committee meeting of 4 December 2024, FDA evaluated five related bulk substances (CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate and CJC-1295 DAC trifluoroacetate) and concluded that a balancing of its four criteria weighs against placing any of them on the 503A bulks list, citing inconsistent naming and incomplete characterisation, unclear history of compounding use, nonclinical safety signals and absent effectiveness data. The committee voted against all five. FDA also lists CJC-1295 among the bulk substances that may present significant safety risks in compounding.
The HHS policy of 28 October 2026 does not cover it. That enforcement-discretion policy applies to six named peptides only: BPC-157 acetate, TB-500 acetate, MOTS-c acetate, Epitalon acetate, Semax free base and KPV acetate. CJC-1295 is not among them, in any form, so nothing in that policy changes its status.
Prohibited in sport at all times. The 2026 WADA Prohibited List, in force since 1 January 2026, places growth hormone releasing factors in section S2.2.4 and names CJC-1295 explicitly among GHRH analogues, alongside CJC-1293, sermorelin and tesamorelin. Section S2 is prohibited at all times, in competition and out of competition, and the wording is non-exhaustive: a substance that is not named can still fall under the category by structure or biological effect. Anti-doping laboratories have published validated mass-spectrometry methods that detect GHRH analogues including CJC-1295 in urine (Uçaktürk and Nemutlu 2026).
What the evidence does not show
No clinical outcome has been demonstrated. The published human evidence consists of pharmacokinetic and pharmacodynamic work in healthy volunteers: it shows that CJC-1295 with DAC raises GH and IGF-1 and for how long, and nothing more. Across the three published human studies FDA reviewed, 63 healthy adults received the peptide, 87 percent of them men and 73 percent of them receiving a single injection. No trial has shown a benefit on any clinical endpoint: not lean or fat mass, not bone density, not sleep architecture, not muscle function, not quality of life. The benefits described earlier in this guide are hypotheses derived from the known biology of the GH/IGF-1 axis, not demonstrated results.
The phase 2 data do not exist in the literature. The only trial conducted in patients rather than healthy volunteers was terminated and never published, so there is no peer-reviewed account of its efficacy, of its adverse events, or of what happened to the other participants. No phase 3 trial has ever been run.
Long-term safety is unstudied, and the nonclinical record is not clean. FDA's 2024 evaluation reports injection-site hemorrhage, inflammation and necrosis consistently observed in rats and dogs given repeated daily subcutaneous injections for up to 14 days, genotoxic signals in vitro and in vivo, and an absence of carcinogenicity studies, which means the potential for pituitary hyperplasia and tumours under long-term stimulation cannot be ruled out. FDA also flags immunogenicity as a concern for an injectable peptide whose aggregation and impurity profile depend on the manufacturing process. There is no safety information in children, none in adults with growth hormone deficiency, and no data at all on four of the five bulk forms that are sold.
Recommended products
Research peptides selected for quality and purity:
CJC-1295 + Ipamorelin
Growth Blend
CJC-1295
Growth Peptide
Ipamorelin
Growth Peptide
Test your knowledge
Quick quiz · 6 questions
CJC-1295: all our articles
- CJC-1295 Side Effects: What the Research Actually Shows
- Where to Buy CJC-1295 in 2026
- The CJC-1295 and Ipamorelin Stack: What the Research Actually Describes
- Ipamorelin vs CJC-1295: Complementary Mechanisms, Optimal Stack and Dosing
- CJC-1295 Dosage and Reconstitution: What the Research Literature Actually Reports
- Where to Buy CJC-1295 + Ipamorelin: A Research Buyer's Guide
Frequently Asked Questions
What is the difference between CJC-1295 DAC and CJC-1295 without DAC (Mod GRF 1-29)?
Is CJC-1295 approved for medical use?
Is CJC-1295 banned in sports?
What are the risks of chronic elevation of GH and IGF-1?
Why do molecular weight and formula figures for CJC-1295 differ between sources?
Did CJC-1295 ever reach phase 3 trials?
Scientific Sources
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. (PubMed)
- Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797. (PubMed · DOI)
- Alba M, Fintini D, Sagazio A, et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294. (PubMed)
- Jetté L, Léger R, Thibaudeau K, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology, 146(7), 3052-3058. (PubMed · DOI)
- Friedman SD, Baker LD, Borber S, et al. (2013). Growth hormone-releasing hormone effects on brain gamma-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurology, 70(7), 883-890. (PubMed · DOI)
- Dominikowski A, Rękoś Z, Olejarz M, et al. (2026). The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology, 17, 1822475. (PubMed · DOI)
- Mendias CL, Awan TM. (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine, 56(8), 1921-1935. (PubMed · DOI)
- Uçaktürk E, Nemutlu E. (2026). Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 268, 117207. (PubMed · DOI)
- U.S. Food and Drug Administration. (2024). FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: CJC-1295-related bulk drug substances. U.S. Food and Drug Administration. (fda.gov)
- World Anti-Doping Agency. (2026). The 2026 Prohibited List, World Anti-Doping Code, section S2.2.4 (growth hormone releasing factors). Council of Europe Anti-Doping Convention appendix, Tractatenblad 2026, 25. (zoek.officielebekendmakingen.nl)
- ConjuChem Biotechnologies Inc. (2006). A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (terminated phase 2 trial). ClinicalTrials.gov, NCT00267527. (clinicaltrials.gov)